Testosterone Replacement Therapy Slows the Effect of COPD


Research suggests that testosterone replacement therapy on middle-aged and older men with COPD reduces the progression of respiratory diseases and hospitalization risks significantly.

A team of researchers at the University of Texas Medical Branch at Galveston studied testosterone replacement therapy and its association with chronic obstructive pulmonary disease. According to World Health Organization, chronic obstructive pulmonary disease, or COPD, is predicted to be the third largest factor for causing illness and death, globally by the end of 2030.

Men suffering with chronic obstructive pulmonary disease are commonly found with low testosterone levels as the steroids taken for the disease effects the productions of testosterone hormone. Previous research work suggested that testosterone replacement therapy may have a positive effect on lung function in men with COPD.

The study aimed to find the effects of testosterone replacement therapy on middle-aged and older men with COPD and the risk associated to them. They collected data from the Clinformatics Data Mart of around 450 men aged between 40 to 63 years with COPD, who began testosterone replacement therapy between 2005 and 2014. Another data compilation was done from Medicare database of around 253 men with COPD aged 65 years or above and those who had undergone testosterone replacement therapy between 2008 and 2013.

The team observed that testosterone replacement therapy may slow the progression of disease in men with COPD. Around 4.2 percent decrease in hospitalization due to respiratory disease was found in middle-aged testosterone replacement therapy users when compared with the non-users. The older aged testosterone replacement therapy users showed a 9.1 percent of decrease in respiratory hospitalizations than the non-users.

The findings were published in the journal Chronic Respiratory Disease on September 2018, titled: “Testosterone replacement therapy and hospitalization rates in men with COPD.”



Comments are closed.